177Lu-PSMA-617 Transport in Solid Tumors via a 3D Image-based Spatio-temporal Model

Anahita  Piranfar; Madjid  Soltani; Farshad  Kashkooli; Wenbo Zhan; Ajay Bhandari; Arman Rahmim

177Lu-PSMA-617 Transport in Solid Tumors via a 3D Image-based Spatio-temporal Model

Anahita Piranfar, Madjid Soltani^*, Farshad Kashkooli, Wenbo Zhan, Ajay Bhandari, Arman Rahmim

^*Corresponding author for this work

Engineering

Research output: Contribution to journal › Abstract › peer-review

Abstract

Radiopharmaceutical therapy (RPT) via the utilization of radioligands enables targeted delivery of radionuclides to cancer cells while keeping radiation exposure to untargeted cells low. An example application of tremendous value includes prostate-specific membrane antigen (PSMA) targeted RPTs of prostate cancer. Noninvasive magnetic resonance (MR) imaging has been widely used for pretreatment workup in patients with prostate cancer. We developed a 3D spatiotemporal drug delivery model based on patient MR imaging data to capture the essential pharmacokinetic interactions between PSMA radioligands and solid prostate tumors. This study is aimed to determine the effects of receptor density, recycling rate, and synthesis rate of PSMA receptors on the mean concentration of 177Lu-PSMA-617 in the tumor.

Original language	English
Pages (from-to)	P811
Number of pages	1
Journal	Journal of Nuclear Medicine
Volume	64
Issue number	S1
Publication status	Published - 1 Jun 2023
Event	Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2023 - McCormick Place, Chicago, IL, United States Duration: 24 Jun 2023 → 27 Jun 2023 https://am.snmmi.org/iMIS/SNMMI-AM

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://jnm.snmjournals.org/content/64/supplement_1/P811Licence: Unspecified

Cite this

@article{6c740b0ecf324797bb5b3eb1a75d4ff6,

title = "177Lu-PSMA-617 Transport in Solid Tumors via a 3D Image-based Spatio-temporal Model",

abstract = "Radiopharmaceutical therapy (RPT) via the utilization of radioligands enables targeted delivery of radionuclides to cancer cells while keeping radiation exposure to untargeted cells low. An example application of tremendous value includes prostate-specific membrane antigen (PSMA) targeted RPTs of prostate cancer. Noninvasive magnetic resonance (MR) imaging has been widely used for pretreatment workup in patients with prostate cancer. We developed a 3D spatiotemporal drug delivery model based on patient MR imaging data to capture the essential pharmacokinetic interactions between PSMA radioligands and solid prostate tumors. This study is aimed to determine the effects of receptor density, recycling rate, and synthesis rate of PSMA receptors on the mean concentration of 177Lu-PSMA-617 in the tumor.",

author = "Anahita Piranfar and Madjid Soltani and Farshad Kashkooli and Wenbo Zhan and Ajay Bhandari and Arman Rahmim",

year = "2023",

month = jun,

day = "1",

language = "English",

volume = "64",

pages = "P811",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "S1",

note = "Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2023, SNMMI 2023 ; Conference date: 24-06-2023 Through 27-06-2023",

url = "https://am.snmmi.org/iMIS/SNMMI-AM",

}

TY - JOUR

T1 - 177Lu-PSMA-617 Transport in Solid Tumors via a 3D Image-based Spatio-temporal Model

AU - Piranfar, Anahita

AU - Soltani, Madjid

AU - Kashkooli, Farshad

AU - Zhan, Wenbo

AU - Bhandari, Ajay

AU - Rahmim, Arman

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Radiopharmaceutical therapy (RPT) via the utilization of radioligands enables targeted delivery of radionuclides to cancer cells while keeping radiation exposure to untargeted cells low. An example application of tremendous value includes prostate-specific membrane antigen (PSMA) targeted RPTs of prostate cancer. Noninvasive magnetic resonance (MR) imaging has been widely used for pretreatment workup in patients with prostate cancer. We developed a 3D spatiotemporal drug delivery model based on patient MR imaging data to capture the essential pharmacokinetic interactions between PSMA radioligands and solid prostate tumors. This study is aimed to determine the effects of receptor density, recycling rate, and synthesis rate of PSMA receptors on the mean concentration of 177Lu-PSMA-617 in the tumor.

AB - Radiopharmaceutical therapy (RPT) via the utilization of radioligands enables targeted delivery of radionuclides to cancer cells while keeping radiation exposure to untargeted cells low. An example application of tremendous value includes prostate-specific membrane antigen (PSMA) targeted RPTs of prostate cancer. Noninvasive magnetic resonance (MR) imaging has been widely used for pretreatment workup in patients with prostate cancer. We developed a 3D spatiotemporal drug delivery model based on patient MR imaging data to capture the essential pharmacokinetic interactions between PSMA radioligands and solid prostate tumors. This study is aimed to determine the effects of receptor density, recycling rate, and synthesis rate of PSMA receptors on the mean concentration of 177Lu-PSMA-617 in the tumor.

M3 - Abstract

SN - 0161-5505

VL - 64

SP - P811

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - S1

T2 - Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2023

Y2 - 24 June 2023 through 27 June 2023

ER -

177Lu-PSMA-617 Transport in Solid Tumors via a 3D Image-based Spatio-temporal Model

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this